利福喷丁

更新时间：2025-08-22 20:22:09

利福喷丁结构式	常用名	利福喷丁	英文名	Rifapentine
	CAS号	61379-65-5	分子量	877.031
	密度	1.4±0.1 g/cm3	沸点	969.3±65.0 °C at 760 mmHg
	分子式	C₄₇H₆₄N₄O₁₂	熔点	179-180ºC
	MSDS	中文版美版	闪点	540.0±34.3 °C
	符号	GHS07	信号词	Warning

利福喷丁用途

Rifapentine (Priftin; DL 473)是抗生素,可用于肺结核。

中文名	利福喷丁
英文名	rifapentine
中文别名	环戊哌嗪利福霉素 \| 3-(4-环戊基-1-哌嗪基-亚氨甲基)-利福霉素
英文别名	更多

描述	Rifapentine (Priftin; DL 473)是抗生素,可用于肺结核。
相关类别	信号通路 >> 抗感染 >> 细菌研究领域 >> 感染
参考文献	[1]. Sharma, S.K., et al., Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev, 2013. 7: p. CD007545.

密度	1.4±0.1 g/cm3
沸点	969.3±65.0 °C at 760 mmHg
熔点	179-180ºC
分子式	C₄₇H₆₄N₄O₁₂
分子量	877.031
闪点	540.0±34.3 °C
精确质量	876.452087
PSA	216.66000
LogP	2.58
InChIKey	WDZCUPBHRAEYDL-PWXWUWFUSA-N
SMILES	COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c(C=NN5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C
外观性状	红色-棕色结晶粉末
蒸汽压	0.0±0.3 mmHg at 25°C
折射率	1.625
储存条件	-20°C Freezer
水溶解性	methanol: soluble2mg/mL, clear, red to red-brown
分子结构	1、摩尔折射率：229.12 2、摩尔体积（cm³/mol）：648.0 3、等张比容（90.2K）：1717.2 4、表面张力（dyne/cm）：49.3 5、极化率（10-24cm3）：90.83
更多	1.性状：从乙酸乙酯结晶。 2.熔点：179～180℃。 3.UV最大吸收：475，334nm(ε15200，26700)。

利福喷丁毒理学数据:

急性毒性LD₅₀小鼠(mg/kg)：＞2000口服，750腹腔注射。也有报道急性毒性LD₅₀小鼠(mg/kg)：3300口服，710腹腔注射。

利福喷丁毒性英文版

符号	GHS07
信号词	Warning
危害声明	H315-H319-H335
警示性声明	P261-P305 + P351 + P338
危害码 (欧洲)	Xi
风险声明 (欧洲)	36/37/38
安全声明 (欧洲)	26
危险品运输编码	NONH for all modes of transport
RTECS号	JQ0902000
海关编码	2941903000

0.01ml的3-醛基利福霉素SV溶于四氢呋喃，在室温下加入0.011mol的1-氨基-4-环戊基哌嗪。反应用薄层跟踪，至原料点消失，约需麟。蒸去溶剂，剩余物用乙酸乙酯重结晶，得利福喷汀，收率55%，熔点179～180℃。 61379-65-5 preparation

海关编码	2941903000

Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.

Antimicrob. Agents Chemother. 58(6) , 3168-76, (2014)

Predicting drug-drug interactions (DDIs) related to cytochrome P450 (CYP), such as CYP3A4 and one of the major drug transporters, P-glycoprotein (P-gp), is crucial in the development of future chemoth...

Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.

Mol. Pharm. 12 , 2594-603, (2015)

Colistin has been increasingly used for the treatment of respiratory infections caused by Gram-negative bacteria. Unfortunately parenteral administration of colistin can cause severe adverse effects. ...

Bacteriological characterization of a Mycobacterium parascrofulaceum strain isolated from a Chinese pneumonia patient.

Int. J. Infect. Dis. 25 , 82-7, (2014)

A Mycobacterium parascrofulaceum strain was isolated from a pneumonia patient-the first such reported case from China. The bacteriological characteristics of the strain were determined.Species identif...

rifamycin-S

Rifamycin-B-tripropyl-hydrazid

(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-{[(4-Cyclopentyl-1-piperazinyl)imino]methyl}-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracy ;clo[23.3.1.1.0]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl acetate

Rifapentine

rifamycin-B tripropylhydrazide

2,7-(Epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-8-[[(4-cyclopentyl-1-piperazinyl)imino]methyl]-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-

EINECS 262-743-9